US biopharmaceutical company Gilead Sciences has confirmed that it is to invest €60m in a new plant at Grange Castle Business Park in Clondalkin in Dublin.
The company's main area of activity is developing treatments for infectious diseases such as HIV and hepatitis.
The new development will involve moving Gilead's existing facilities and 80 staff from its current location at Sandyford Industrial Estate. The company says it expects to also create 80 new jobs.
Gilead will submit a planning application for the new site by the end of this month and hopes to complete construction by the end of 2008.
Among its main Irish activities is the supply of anti-HIV medication to developing countries.
